Orgenesis Inc. 3Y Net Income Growth (per Share)

3Y Net Income Growth (per Share) of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including 3Y Net Income Growth (per Share) growth rates and interactive chart.

Highlights and Quick Summary

  • Annual 3Y Net Income Growth (per Share) for 2020 was 0.0% (a NaN% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical 3Y Net Income Growth (per Share) of Orgenesis Inc.

Most recent 3Y Net Income Growth (per Share)of ORGS including historical data for past 10 years.

Interactive Chart of 3Y Net Income Growth (per Share) of Orgenesis Inc.

Orgenesis Inc. 3Y Net Income Growth (per Share) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0%
2019 0.0%

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.